Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

  • Shaji K Kumar
  • , Natalie S Callander
  • , Kehinde Adekola
  • , Larry D Anderson
  • , Muhamed Baljevic
  • , Rachid Baz
  • , Erica Campagnaro
  • , Jorge J Castillo
  • , Caitlin Costello
  • , Christopher D'Angelo
  • , Benjamin Derman
  • , Srinivas Devarakonda
  • , Noura Elsedawy
  • , Alfred Garfall
  • , Kelly Godby
  • , Jens Hillengass
  • , Leona Holmberg
  • , Myo Htut
  • , Carol Ann Huff
  • , Malin Hultcrantz
  • Yubin Kang, Sarah Larson, Hans Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Jenna Snedeker, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Original languageEnglish
Article numbere240001
Pages (from-to)1-19
Number of pages19
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume22
Issue number1D
DOIs
StatePublished - Jan 2024

Keywords

  • Humans
  • Lymphoma, B-Cell
  • Waldenstrom Macroglobulinemia/therapy

Fingerprint

Dive into the research topics of 'Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology'. Together they form a unique fingerprint.

Cite this